<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01415778</url>
  </required_header>
  <id_info>
    <org_study_id>D6874L00025</org_study_id>
    <nct_id>NCT01415778</nct_id>
  </id_info>
  <brief_title>Bioequivalence of ICI176,334-1 in Japanese Healthy Male Subjects</brief_title>
  <official_title>Bioequivalence Study of ICI176,334-1 in Japanese Healthy Male Subjects - Evaluation of Bioequivalence of ICI176,334-1 and Casodex 80 mg Tablet -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the bioequivalence of ICI176,334-1 in Japanese
      healthy male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bioequivalence study of ICI176,334-1 in Japanese healthy male subjects - evaluation of
      bioequivalence of ICI176,334-1 and Casodex 80 mg tablet -
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the bioequivalence of ICI176,334-1 by assessment of maximum plasma concentration (Cmax)</measure>
    <time_frame>Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the bioequivalence of ICI176,334-1 by assessment of time to Cmax (tmax)</measure>
    <time_frame>Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the bioequivalence of ICI176,334-1 by assessment of area under the plasma concentration curve (AUC)</measure>
    <time_frame>Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the bioequivalence of ICI176,334-1 by assessment of t1/2 of bicalutamide</measure>
    <time_frame>Blood samples are taken repeatedly for 72 hours and also taken occasionally up to 672 hours after each dose period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety by assessment of adverse event</measure>
    <time_frame>Screening day up to 35 to 42 days (follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety by assessment of vital signs</measure>
    <time_frame>Collect prior to treatment and up to 35 to 42 days (follow-up) after the last dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the safety by assessment of electrocardiograms (ECGs)</measure>
    <time_frame>Collect prior to treatment and up to 35 to 42 days (follow-up) after the last dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Active 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects will receive ICI176,334-1 and Casodex 80 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI176,334-1</intervention_name>
    <description>Subject will receive single dose of ICI176,334-1</description>
    <arm_group_label>Active 1</arm_group_label>
    <arm_group_label>Active 2</arm_group_label>
    <arm_group_label>Active 3</arm_group_label>
    <arm_group_label>Active 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Casodex 80 mg tablet</intervention_name>
    <description>Subject will receive single dose of Casodex 80 mg tablet</description>
    <arm_group_label>Active 1</arm_group_label>
    <arm_group_label>Active 2</arm_group_label>
    <arm_group_label>Active 3</arm_group_label>
    <arm_group_label>Active 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures

          -  Japanese healthy male subjects aged 20 to 45 years

          -  Male subjects should be willing to use barrier contraception ie, condoms, until 3
             months after the last dose of investigational product

          -  Have a body mass index (BMI) between 17 and 27 kg/m2

          -  Eligible based on the physical findings, supine BP, pulse rate, ECG and laboratory
             assessments, as judged by the investigator(s)

        Exclusion Criteria:

          -  Presence of any disease under medical treatment

          -  History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             immunological, blood, endocrine, neurological or mental disease to interfere with
             absorption, distribution, metabolism or excretion of drugs judged by investigator(s)

          -  Presence of any infectious disease, such as bacteria, virus and fungus

          -  Presence of allergic disorder, such as asthma, pollen disease or atopic dermatitis,
             and judged as necessary any medical treatment

          -  Any large surgical history of gastrointestinal tract such as gastric/intestinal
             resection or suturation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <keyword>bicalutamide</keyword>
  <keyword>Casodex</keyword>
  <keyword>Japanese</keyword>
  <keyword>healthy subject</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

